TY - JOUR
T1 - Bosutinib
T2 - A third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia
AU - Hill, Brittany G.
AU - Kota, Vamsi K.
AU - Khoury, Hanna Jean
PY - 2014/7
Y1 - 2014/7
N2 - Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). Bosutinib is a very effective TKI against all phases of intolerant or resistant CML regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable T315I or V299L. Bosutinib is overall well tolerated and associated with a unique, but manageable toxicity profile. Factors that influence the prescribing pattern of this drug are complex and include physicians', and increasingly patients and families' preference, patients' comorbid conditions, schedule of administration, as well as financial factors. This paper provides an overview of CML, the TKI market, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of bosutinib.
AB - Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). Bosutinib is a very effective TKI against all phases of intolerant or resistant CML regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable T315I or V299L. Bosutinib is overall well tolerated and associated with a unique, but manageable toxicity profile. Factors that influence the prescribing pattern of this drug are complex and include physicians', and increasingly patients and families' preference, patients' comorbid conditions, schedule of administration, as well as financial factors. This paper provides an overview of CML, the TKI market, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of bosutinib.
KW - Bosutinib
KW - Chronic myeloid leukemia
KW - Resistant
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84903161718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903161718&partnerID=8YFLogxK
U2 - 10.1586/14737140.2014.924400
DO - 10.1586/14737140.2014.924400
M3 - Review article
C2 - 24875651
AN - SCOPUS:84903161718
SN - 1473-7140
VL - 14
SP - 765
EP - 770
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 7
ER -